Research Paper Volume 13, Issue 16 pp 20468—20480

The efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating advanced urothelial cancer: a meta-analysis of clinical trials

Forest plot of the efficacy of immune checkpoint inhibitors in treating patients with advanced urothelial cancer. (A) Pooled objective response rate. (B) Pooled 1-year overall survival rate. (C) Pooled 1-year progress free survival rate. The diamonds represent the pooled indexes. The line crossing the square represents the 95% CI. I2 indicates the heterogeneity in each subgroup meta-analysis. P demonstrates the significance of differences between the subgroups.

Figure 2. Forest plot of the efficacy of immune checkpoint inhibitors in treating patients with advanced urothelial cancer. (A) Pooled objective response rate. (B) Pooled 1-year overall survival rate. (C) Pooled 1-year progress free survival rate. The diamonds represent the pooled indexes. The line crossing the square represents the 95% CI. I2 indicates the heterogeneity in each subgroup meta-analysis. P demonstrates the significance of differences between the subgroups.